develop
effect
vaccin
enhanc
rsv
ill
import
understand
formalin
heat
inactiv
affect
antigen
immunogen
firsv
compar
nativ
viru
inform
atom
structur
rsv
fusion
f
glycoprotein
prefus
pref
postfus
postf
conform
demonstr
firsv
predomin
present
postf
virion
surfac
wherea
infecti
rsv
present
pref
postf
conform
signific
antigen
distinct
previous
appreci
thu
stabil
pref
antigen
repres
live
rsv
f
postf
conform
display
surfac
firsv
find
major
implic
discrimin
current
prefbas
immunogen
firsv
use
histor
vaccin
trial
respiratori
syncyti
viru
rsv
envelop
nonseg
negativesens
singlestrand
rna
viru
caus
upper
lower
respiratori
tract
infect
nearli
everyon
infect
viru
first
two
year
life
reinfect
occur
throughout
life
diseas
sever
highest
infant
elderli
rsv
repres
seriou
health
econom
burden
lead
caus
hospit
children
age
ref
despit
rsv
discov
nearli
year
ago
licens
vaccin
yet
avail
part
delay
develop
stem
clinic
trial
use
formalininactiv
rsv
firsv
product
caus
enhanc
respiratori
diseas
erd
syndrom
children
receiv
firsv
vaccin
firsv
vaccin
adjuv
alum
evalu
four
separ
studi
seroneg
infant
young
children
ref
instead
elicit
protect
immun
greater
number
vaccine
develop
sever
ill
compar
control
group
three
dose
regimen
month
use
subject
month
age
hospit
infect
children
firsvvaccin
group
n
compar
hospit
infect
control
group
n
tragic
two
firsv
recipi
die
month
age
bacteri
pneumonia
complic
subsequ
rsv
infect
major
vaccine
prime
firsv
led
patholog
upon
subsequ
rsv
infect
ordinarili
manifest
small
fraction
individu
immunolog
basi
firsvinduc
enhanc
ill
focus
two
major
featur
humor
cellular
respons
first
firsv
induc
high
titer
bind
antibodi
weak
neutral
fusioninhibitori
activ
antibodi
context
larg
antigen
load
led
immun
complex
deposit
complement
activ
airway
upon
subsequ
rsv
infect
second
natur
rsv
infect
immun
firsv
associ
exagger
peribronchiolar
inflamm
infiltr
neutrophil
eosinophil
airway
consist
find
anim
model
firsv
shown
induc
immun
respons
airway
hypersensit
character
regul
ige
importantli
firsv
vaccin
result
enhanc
rsv
diseas
individu
first
prime
live
viru
infect
attenu
replicationcompet
vaccin
given
intranas
parenter
indic
immunolog
prime
firsv
vaccin
respons
aberr
respons
subsequ
infect
therefor
develop
effect
vaccin
enhanc
rsv
ill
upon
subsequ
infect
young
infant
import
understand
viral
inactiv
affect
antigen
immunogen
firsv
compar
nativ
viru
formalin
aqueou
formaldehyd
treatment
longestablish
method
inactiv
virus
high
concentr
formalin
fix
tissu
obliter
infect
form
chemic
addit
carbonyl
intraand
interprotein
crosslink
lower
concentr
howev
modif
vari
effect
preserv
antigen
site
hepat
viru
vaccin
inactiv
formalin
elicit
antibodi
human
neutral
viru
protect
infect
howev
polioviru
inactiv
formalin
shown
decreas
bind
human
polioviru
receptor
suggest
formalin
inactiv
alter
receptorbind
site
data
suggest
formalin
potenti
fix
stabil
protein
conform
alter
protein
structur
andor
chemic
modifi
protein
surfac
unknown
heat
formalin
treatment
use
produc
firsv
would
affect
conform
antigen
content
rsv
fusion
glycoprotein
f
virion
surfac
surfac
rsv
decor
surfac
protein
includ
fusion
protein
f
attach
protein
g
small
hydrophob
sh
pentamer
ion
channel
g
may
play
role
attach
airway
epithelium
immunomodul
f
glycoprotein
major
target
vaccin
develop
due
requir
viral
entri
high
sequenc
conserv
f
type
transmembran
protein
cleav
furinlik
proteas
aa
peptid
aa
aa
form
trimer
heterodim
atomiclevel
structur
f
determin
two
distinct
conform
prefus
postfus
pref
postf
respect
fig
b
similarli
class
fusion
protein
rsv
f
undergo
massiv
conform
rearrang
mediat
viralcel
membran
fusion
transit
irrevers
metast
pref
stabl
postf
conform
although
pref
postf
structur
distinct
shape
share
roughli
surfac
area
includ
two
welldefin
antigen
site
ii
iv
moder
neutral
sensit
uniqu
surfac
pref
least
three
addit
antigen
site
report
far
iii
v
highli
neutral
sensit
particularli
site
fig
antibodi
bind
antigen
site
weak
neutral
activ
bind
almost
exclus
postf
pref
postf
present
membran
infecti
rsv
neutral
antibodi
respons
found
natur
infect
individu
year
age
predominantli
direct
toward
pref
surfac
signific
neutral
activ
rsv
fspecif
antibodi
recogn
interrupt
pref
function
time
firsv
product
clinic
evalu
thought
although
formalin
treatment
would
render
rsv
noninfecti
would
interfer
antigen
properti
viru
studi
later
show
firsv
induc
rel
high
titr
bind
antibodi
low
neutral
activ
hint
firsv
may
recapitul
antigen
surfac
infecti
rsv
structur
analys
detail
epitop
monoclon
antibodi
mab
bind
pref
postf
yield
tool
make
figur
assess
stabil
pref
firsv
product
dot
blot
demonstr
motavizumab
recognit
antigen
site
ii
recognit
quaternari
antigen
site
v
recognit
antigen
site
rsv
incub
concentr
formalin
interv
averag
antibodi
bind
virion
report
rel
antibodi
bind
pref
protein
load
control
error
bar
repres
standard
deviat
three
experi
signific
differ
popul
calcul
oneway
anova
note
graphic
ns
signific
p
p
p
p
recognit
antigen
site
ii
present
pref
postf
surfac
preserv
treatment
high
temperatur
dilut
concentr
formalin
contrast
dot
blot
demonstr
prefspecif
mab
rapidli
lose
reactiv
virion
incub
dilut
concentr
formalin
antigen
character
dot
blot
use
mab
either
target
antigen
site
ii
share
surfac
pref
postf
motavizumab
epitop
uniqu
pref
fig
show
four
antibodi
recogn
freshli
purifi
rsv
firsv
recogn
motavizumab
fig
experi
use
conform
stabil
prefus
f
protein
pref
specif
antibodi
abl
recogn
incub
without
addit
formalin
indic
loss
recognit
firsv
pref
specif
antibodi
due
chemic
modif
formalin
rather
due
modif
pref
conform
investig
effect
formalin
antigen
recognit
increas
concentr
ad
formalin
found
recognit
postf
motavizumab
antibodi
greatli
reduc
supplementari
fig
indic
formalin
influenc
antigen
effect
discern
formalininactiv
concentr
much
less
impact
temperatur
understand
effect
formalin
elev
temperatur
antigen
profil
rsv
virion
recapitul
method
use
manufactur
firsv
defin
kinet
antibodi
reactiv
immedi
applic
formalin
rsv
retain
pref
postf
antigen
site
howev
time
pref
specif
epitop
surfac
rsv
disappear
fig
disappear
pref
specif
epitop
particularli
site
correl
reduct
infect
determin
flow
cytometri
recombin
gfpexpress
rsvinfect
cell
fig
similar
correl
diminish
trimer
bind
loss
infect
observ
viru
incub
differ
temperatur
rang
presenc
formalin
fig
b
reactiv
motavizumab
remain
rel
stabl
everi
temperatur
viru
incub
close
room
temperatur
maintain
pref
epitop
bind
longer
virus
incub
human
bodi
temperatur
mous
bodi
temperatur
data
indic
pref
surfac
virion
convert
postf
quickli
temperatur
room
temperatur
hour
origin
firsv
remain
pref
class
fusion
protein
rsv
f
share
properti
surfac
glycoprotein
envelop
virus
parainfluenza
viru
fusion
f
influenza
hemagglutinin
ha
envelop
env
ebola
glycoprotein
gp
coronaviru
spike
protein
mediat
membran
fusion
conform
chang
prefus
form
transit
prehairpin
intermedi
form
eventu
stabl
bundl
postfus
form
therefor
defin
protein
conform
present
surfac
viral
immunogen
key
understand
mechan
antibodi
neutral
repres
import
step
toward
design
vaccin
immunogen
target
function
prefus
conform
recent
work
env
demonstr
contrast
strainspecif
antibodi
rais
monom
nonn
trimer
stabil
version
prefus
env
trimer
preferenti
elicit
conformationdepend
crossreact
antibodi
effect
target
function
prefus
conform
similarli
critic
differ
antigen
site
pref
infecti
rsv
postf
firsv
suggest
balanc
f
conform
state
determin
viru
infect
design
immunogen
preserv
neutralizationsensit
epitop
function
form
viral
protein
promot
induct
protect
antibodi
respons
diminish
nonneutr
antibodi
respons
theoret
reduc
likelihood
immun
complex
format
complement
activ
studi
mice
macaqu
shown
stabil
pref
immunogen
elicit
potent
neutral
antibodi
respons
titer
high
end
achiev
recurr
natur
infect
human
hour
time
use
make
firsv
vaccin
presenc
prefspecif
epitop
virion
surfac
membran
nearli
complet
lost
fig
contradict
origin
presumpt
product
firsv
rsv
alter
infect
viru
antigen
low
concentr
formalin
would
help
preserv
fix
antigen
site
viru
catastroph
failur
tragedi
result
firsv
vaccin
trail
restrict
consider
use
proteinbas
rsv
vaccin
infant
defin
atomiclevel
detail
rsv
f
two
distinct
conform
well
isol
character
mab
distinguish
surfac
uniqu
function
pref
nonfunct
postf
provid
new
reagent
defin
antigen
firsv
addit
piec
firsvinduc
vaccineenhanc
diseas
puzzl
anticip
vaccin
design
base
understand
relationship
conform
state
specif
immun
respons
guid
develop
effect
vaccin
rsv
potenti
viral
diseas
antigen
analysi
antigen
character
perform
dot
blot
use
mab
either
target
antigen
site
ii
share
surfac
pref
postf
motavizumab
epitop
uniqu
pref
surfac
briefli
dot
pref
postf
heat
inactiv
pref
hipref
formalin
inactiv
pref
fipref
rsv
firsv
appli
nitrocellulos
membran
probe
antibodi
motavizumab
made
hous
similarli
western
blot
probe
hrpconjug
secondari
antibodi
reactiv
either
human
goat
antihuman
igghrp
santa
cruz
biotechnolog
mous
rabbit
antimous
igghrp
jackson
immunoresearch
fc
region
hiand
fipref
incub
hour
fipref
includ
concentr
formalin
pref
includ
concentr
formalin
antibodi
incub
one
hour
room
temperatur
skim
milk
tbst
concentr
antibodi
bind
detect
via
gbox
gel
imag
syngen
densitometri
done
use
genetool
syngen
antibodi
bind
postf
virion
report
rel
antibodi
bind
pref
protein
load
control
time
cours
analysi
manufactur
firsv
requir
rsv
expos
formalin
hour
produc
firsv
incub
rsv
formalin
hour
virus
sampl
antigen
analysi
infect
everi
hour
hourinterv
incub
infect
rsv
express
gfp
strain
incub
concentr
formalin
sampl
period
infect
cell
infect
monitor
function
gfp
express
encod
viral
genom
hour
postinfect
flow
cytometri
lsr
ii
bd
bioscienc
ca
usa
prior
assess
flow
cytometri
cell
treat
mm
edta
ensur
singlecel
suspens
optim
analysi
fix
paraformaldehyd
one
hundr
percent
infect
repres
number
cell
infect
rsv
prior
incub
